.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Argus Health
Colorcon
McKinsey
Teva
Cantor Fitzgerald
Fish and Richardson
Cerilliant
Cipla

Generated: February 25, 2018

DrugPatentWatch Database Preview

Regulatory Exclusivity Expiring in 2021

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Exclusivity Expiration Patented / Exclusive Use
Vertex Pharms IncORKAMBIivacaftor; lumacaftorTABLET;ORAL206038-001Jul 2, 2015RXYesYes➤ Sign UpPEDIATRIC EXCLUSIVITY
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-003May 29, 2013RXYesYes➤ Sign UpTRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-002May 29, 2013DISCNYesNo➤ Sign UpTRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo➤ Sign UpTRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-002May 29, 2013RXYesYes➤ Sign UpDABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-001May 29, 2013RXYesNo➤ Sign UpDABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
Boehringer IngelheimGILOTRIFafatinib dimaleateTABLET;ORAL201292-003Jul 12, 2013RXYesYes➤ Sign UpTREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo➤ Sign UpTREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
Boehringer IngelheimGILOTRIFafatinib dimaleateTABLET;ORAL201292-002Jul 12, 2013RXYesNo➤ Sign UpTREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes➤ Sign UpTREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
US Army
Teva
Julphar
Baxter
McKesson
Daiichi Sankyo
McKinsey
Merck
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot